|
|||||||||||||
|
|
||||||||||||
|
|||||||||||||
Asthma Deaths From Use of Inhalers
|
|||||||||||||
|
Becoming Provable In Court, Lawyers Jumping In. Lawyers are now getting involved, when it becomes readily apparent that asthma deaths are primarily drugs administered problem.
http://wwwlawyersandsettlements.com/fea
Four out of five . Asthma-related deaths per year, in the US were linked to asthma inhalers containing the drugs salmeterol or formoterol //. According to researchers from Cornell and Stanford universities, these drugs should be taken off the market . They base these conclusions on a statistical analysis of 19 published trials involving 33,826 patients. This so-called meta-analysis found that patients who inhaled the long-acting beta-agonists salmeterol (trade names Serevent and Advair, both made by GlaxoSmithKline) or formoterol (trade name Foradil, made by Novartis Pharmaceuticals) were 3.5 times more likely to die from asthma and 2.5 times more likely to be hospitalized (whether or not death resulted), compared with those taking a placebo.
Editors Note: The placebo was a different less potent inhaler. (which may itself cause deaths but lessor degree, no studies) The reason, say the researchers, is because although these medications relieve asthma symptoms, they also promote bronchial inflammation and sensitivity without warning. Editors Note: Note the conclusion that these drug treatments you are paying for and taking these drugs results in development of conditions "worsened" by the treatment. This is what we call "escalading" your health problem. Here is another important section of information. Brenda Frohloff Washington, DC: Serevent, the inhaler medication for asthmatics, and Advair, the inhaler combining Serevent and Flovent, continue to be widely prescribed despite a 13-year history of complications. Serevent, Flovent and Advair, manufactured by GlaxoSmithKline, are a wildly successful line of inhaler drugs for the company, but Serevent has been the kiss of death for too many unfortunate users Advair combines both Serevent and Flovent in one inhaler. According to figures for the year 2005, in the U.S. Serevent was prescribed 1.7 million times, Flovent 3.5 million times and Advair 21.1 million times. The sales total for these three inhaler drugs in the U.S. was more than $4 billion... It's easy to see why Glaxo wants to keep a good thing going. One expert, Shelley Salpeter, a clinical professor of medicine at Stanford University, told journalist Robert Langreth last year that as many as 4000 of the 5000 asthma deaths in the U.S. each year could be prevented if patients stopped taking Serevent-style drugs. She says that the patients taking these drugs have been found to have twice the rate of asthma hospitalizations, twice the rate of life-threatening asthma and four times as many deaths as patients who aren't on these drugs. Editors note These are just some of the large amount of information being released on the web regarding use of drugs to treat asthma being part of an escalating of the condition. The FDA has withdrawn some from the market, but the big names above remain on the market, with what is known as "Black Box warnings" which boils down to, "do not say we did not tell you what this stuff does to you."
|
|
||||||||||||
